Greg is a seasoned leader in the biopharmaceutical industry, renowned for his expertise in driving commercialization and strategic development of innovative therapies. With extensive experience across various facets of biopharma, including clinical development, market access, and corporate strategy, Greg has been instrumental in advancing new treatments from early-stage development through to successful market entry.Throughout his career, Greg has worked with both emerging biotech firms and established pharmaceutical companies, leading cross-functional teams to overcome the unique challenges of drug development. His insights into regulatory landscapes, patient access strategies, and commercialization processes have positioned him as a trusted figure in the industry. Greg is particularly adept at building and nurturing partnerships with stakeholders across the healthcare ecosystem, from research organizations and regulatory bodies to providers and patient advocacy groups.Known for his strategic vision and patient-focused approach, Greg continues to make a significant impact on the biopharma industry, helping companies develop therapies that address unmet medical needs and improve patient outcomes. His dedication to innovation and his expertise in navigating the complexities of the biopharma space underscore his ongoing commitment to advancing healthcare solutions.Biotech Exec l Strategy | Execution I Investor RelationsEmail: gregwuj@gmail.comCell: 908-809-3899Areas of Expertise:- P&L Management & Operations- Corporate Strategy development & execution- Raising capital, M&A, IPO & investor relations- Culture & Leadership Development - Business development; tech transfer & licensing - Marketing Plan development & execution- Market Access strategy & contract negotiation- Pricing & financial modeling- Multiple successful product launches - Project Leadership- Sales- Relationship ManagementAccomplishments:- Successfully restructured and led company out of clinical hold to reestablish as a leader in an ultra rare market.- Identified, cultivated and completed the company’s first licensing and $75M acquisition of a cell & gene therapy company